Mark your calendar: On Wednesday, November 6th at 11:00 a.m., the Canadian Real-World Evidence for Value of Cancer Drugs (CanReValue) team will host a webinar to present the development and testing of a framework that will be used to generate and apply real-world evidence (RWE) in funding decisions for cancer drugs.
CanReValue is a collaboration among stakeholders including the ARCC, CADTH/pCODR, CAPCA, Health Canada, INESSS, pCPA, ministries and departments of health, and provincial cancer agencies across Canada. It is now at the stage to share draft reports and invite stakeholder feedback on its work done to date.
The CanReValue framework will be specific for cancer drug funding decisions, however all industry members – including those outside the oncology space – should be especially interested to contribute feedback as this framework could become a precedent for generating and using RWE in a similar manner to what is being proposed by CanReValue for all drug funding across Canada in the years to come.
Importantly, at a time when the pharmaceutical industry is advancing the use of RWE as a mechanism to improve the timeliness and quality of patient access to innovative medicines, the proposed scope by CanReValue needs to consider a balanced approach in using RWE to enhance access and not only on restricting access. Of note, a stated goal of the CanReValue pilot, which deserves particular attention from stakeholders, is to
“develop and test a framework for the generation and use
of real world evidence (RWE) of cancer drugs to enable
(i) reassessment of cancer drugs by recommendation-makers;
and (ii) refinement of funding decisions or renegotiations/
disinvestment by decision-makers/payers across Canada.  “
Register for the webinar here.